Oslo, Norway, November 9, 2026 - Lytix Biopharma ASA (“Lytix”), a clinical-stage oncology company developing novel intratumoral cancer therapies, today announced that its late-breaking abstract presenting updated results from the Phase II NeoLIPA trial has been accepted for oral presentation in a Proffered Paper session at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026. The congress will take place December 14-16, 2026, in London, United Kingdom.
Late-breaking abstracts present new data that were not yet available at the regular abstract submission deadline. The congress Scientific Committee selects abstracts for presentation, and ESMO defines its Proffered Paper format as an “oral presentation of original data of superior quality”. Proffered Paper presentations are also discussed by experts invited by ESMO.
…
Vis børsmeldingen
On November 3, 2026, Lytix announced that NeoLIPA met its primary endpoint. The results will be presented by Henrik Jespersen, MD, Principal Investigator of the NeoLIPA trial at Oslo University Hospital, The Norwegian Radium Hospital. NeoLIPA is an investigator-initiated Phase II study led by Oslo University Hospital in patients with resectable melanoma, the most serious form of skin cancer. The study evaluates ruxotemitide in combination with pembrolizumab before surgery. In line with ESMO’s embargo policy, the data will be made public on the day of presentation.
“We are very pleased that the NeoLIPA abstract has been selected for a Proffered Paper presentation at ESMO IO, and we congratulate Dr. Jespersen and the team at the Norwegian Radium Hospital. We look forward to sharing the results with the scientific and clinical community in December,” said Øystein Rekdal, CEO of Lytix Biopharma.
“Being selected for a Proffered Paper presentation is a great opportunity to share the NeoLIPA results with the international oncology community. I look forward to presenting the updated data in London and discussing them with colleagues working to improve outcomes for patients with melanoma,” said Henrik Jespersen, MD, Principal Investigator of the NeoLIPA trial.
Presentation details
Title: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Melanoma: Updated Results From The Phase II NeoLIPA Trial
Abstract: LBA2
Presenter: Henrik Jespersen, MD, Oslo University Hospital, The Norwegian Radium Hospital
Date & Time: December 15, 2026, 11:40 - 11:50
About NeoLIPA
NeoLIPA is an investigator-initiated, single-arm, open-label Phase II study led by Oslo University Hospital. It evaluates ruxotemitide, administered directly into tumors, in combination with pembrolizumab before surgery in patients with resectable melanoma (ClinicalTrials.gov: NCT06651151, EU CT 2023-508649-42-00). The primary endpoint is pCR. The protocol prespecified a threshold of at least 40% pCR, with the lower bound of the 95% confidence interval above the historical pCR of 20% for pembrolizumab alone.
For more information about NeoLIPA and the treatment approach, visit Lytix Biopharma | Oncolytic Immunotherapy.
About melanoma
Melanoma is the most serious form of skin cancer. In the United States, an estimated 112,000 new cases of invasive melanoma will be diagnosed in 2026, and approximately 8,510 people are expected to die from the disease. Incidence has increased in most Western countries in recent decades, and there is continued interest in effective treatment options before surgery.
About ruxotemitide
Ruxotemitide (LTX-315) is an investigational, first-in-class oncolytic peptide designed for intratumoral administration. The molecule disrupts tumor cells locally, leading to the release of tumor antigens and danger signals that activate systemic antitumor immune responses, with the aim of preventing cancer recurrence. Its mode of action provides a rationale for combination with immune checkpoint inhibitors such as pembrolizumab.
About Lytix Biopharma ASA
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to achieve durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules with potential across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker symbol LYTIX.
For further information, please contact:
Øystein Rekdal, CEO
E-mail: oystein.rekdal@lytixbiopharma.com
Ph +47 975 73 358
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Ph +47 952 60 512
For more information, visit www.lytixbiopharma.com.
Kilde
